Treatment of fibromyalgia syndrome with Super Malic®: A randomized, double blind, placebo controlled, crossover pilot study

I. J. Russell, J. E. Michalek, J. D. Flechas, G. E. Abraham

Research output: Contribution to journalArticlepeer-review

75 Scopus citations

Abstract

Objective. To study the efficacy and safety of Super Malic®, a proprietary tablet containing malic acid (200 mg) and magnesium (50 mg), in treatment of primary fibromyalgia syndrome (FM). Methods. Twenty-four sequential patients with primary FM were randomized to a fixed dose (3 tablets bid), placebo controlled, 4-week/course, pilot trial followed by a 6-month, open label, dose escalation (up to 6 tablets bid) trial. A 2-week, medication free, washout period was required before receiving treatment, between blinded courses, and again before starting open label treatment. The 3 primary outcome variables were measures of pain and tenderness but functional and psychological measures were also assessed. Results. No clear treatment effect attributable to Super Malic® was seen in the blinded, fixed low dose trial. With dose escalation and a longer duration of treatment in the open label trial, significant reductions in the severity of all 3 primary pain/tenderness measures were obtained without limiting risks. Conclusions. These data suggest that Super Malic is safe and may be beneficial in the treatment of patients with FM. Future placebo-controlled studies should utilize up to 6 tablets of Super Malic bid and continue therapy for at least 2 months.

Original languageEnglish (US)
Pages (from-to)953-958
Number of pages6
JournalJournal of Rheumatology
Volume22
Issue number5
StatePublished - May 30 1995

Keywords

  • ATP
  • Fibromyalgia
  • Magnesium
  • Malic acid
  • Treatment

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Treatment of fibromyalgia syndrome with Super Malic®: A randomized, double blind, placebo controlled, crossover pilot study'. Together they form a unique fingerprint.

Cite this